Ritlecitinib (Litfulo®) HTA ID: 23071

Assessment Status Rapid Review Complete
HTA ID 23071
Drug Ritlecitinib
Brand Litfulo®
Indication For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
Assessment Process
Rapid review commissioned 27/11/2023
Rapid review resubmission required 11/12/2023
Rapid review completed 22/12/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care.